|
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
It is unlikely that functional mutations in the GCLM gene could play a major role in genetic predisposition to schizophrenia and further studies will be required to assess its etiological function in the disease.
|
19455074 |
2009 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
In this study, we performed association studies between GSH-related genes (GSTM1, GSTP1, GSTO1, GSTT1, GSTT2, GPX1, and GCLM) and schizophrenia in a Japanese population.
|
18449862 |
2009 |
|
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that a common genetic variation in the GCLM gene might not contribute to the risk of METH-use disorder and schizophrenia in the Japanese population.
|
18991850 |
2008 |
|
Schizophrenia
|
0.340 |
AlteredExpression
|
disease |
LHGDN |
Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.
|
16909399 |
2006 |
|
Myocardial Infarction
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in glutathione-synthesizing (glutamyl-cysteine ligase catalytic subunit, GCLC and glutamyl-cysteine ligase modifier subunit, GCLM) or glutathione-conjugating (glutathione S-transferase P, GSTP1) genes were genotyped in 1027 individuals from northern Sweden (458 cases of first-ever myocardial infarction and 569 matched controls).
|
21504558 |
2011 |
|
Myocardial Infarction
|
0.320 |
Biomarker
|
disease |
CTD_human |
Polymorphism in glutamate-cysteine ligase modifier subunit gene is associated with impairment of nitric oxide-mediated coronary vasomotor function.
|
12975258 |
2003 |
|
Myocardial Infarction
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the -588T polymorphism of the GCLM gene may suppress GCLM gene induction in response to oxidants and that it is a genetic risk factor for MI.
|
12081989 |
2002 |
|
Myocardial Infarction
|
0.320 |
GeneticVariation
|
disease |
LHGDN |
These findings suggest that the -588T polymorphism of the GCLM gene may suppress GCLM gene induction in response to oxidants and that it is a genetic risk factor for MI.
|
12081989 |
2002 |
|
Myocardial Infarction
|
0.320 |
Biomarker
|
disease |
CTD_human |
These findings suggest that the -588T polymorphism of the GCLM gene may suppress GCLM gene induction in response to oxidants and that it is a genetic risk factor for MI.
|
12081989 |
2002 |
|
Shared Paranoid Disorder
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Four SNPs (2 SNPs from an original report and JSNP database, and 2 "tagging SNPs" from HapMap database) in the GCLM gene were examined in this association analysis; one SNP showed an association with both METH-use disorder and METH-induced psychosis.
|
18991850 |
2008 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Psychoses, Drug
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population.
|
18991850 |
2008 |
|
Berylliosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Chronic beryllium disease and glutathione biosynthesis genes.
|
16766924 |
2006 |
|
Beryllium Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Chronic beryllium disease and glutathione biosynthesis genes.
|
16766924 |
2006 |
|
MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
|
|
|
|
Injury of liver
|
0.200 |
Biomarker
|
disease |
RGD |
Schisandra Chinensis Baillon regulates the gene expression of phase II antioxidant/detoxifying enzymes in hepatic damage induced rats.
|
24944771 |
2014 |
|
Tubulointerstitial fibrosis
|
0.200 |
Biomarker
|
phenotype |
RGD |
Proteomics investigation on aristolochic acid nephropathy: a case study on rat kidney tissues.
|
21152904 |
2011 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Glucocorticoid receptor (GCR) knockdown decreased the expression and activity of γ-glutamylcysteine synthetase (γ-GCS), the rate-limiting step in GSH synthesis, in metastatic cells in vivo independent of the tumor location (liver, lung, or subcutaneous).
|
24802641 |
2014 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Both subunits (heavy and light subunits) of gamma-GCS expression levels of normal lung and tumour tissues exposed to platinum drugs during life were significantly higher than those of non-exposed tissues, whereas only the MRP expression levels of tumours were elevated in association with ante-mortem platinum drug exposure.
|
9569044 |
1998 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
More importantly, all of the 16 (100%) MRP-overexpressing tumor specimens also exhibited higher levels of gamma-GCS mRNA than those in the matched nontumorous specimens.
|
8705999 |
1996 |